



A simpler GLP-1, plus big-market launches

The spring Notable New Drug Report highlights GLP-1 drugs with fewer meal-time restrictions, COVID-19 prevention and a pill for plaque psoriasis.

[Read more](#)

Top stories this month

[Relentless preparation leads to a strong 2026 implementation](#)

Careful planning and disciplined execution delivered a record-setting Optum Rx 1/1 implementation season.

[The shifting cost basis for popular drugs](#)

Government price negotiations are reshaping the commercial market – and they will for years to come.

[Using AI to lower costs, reduce pharmacy errors and protect patients](#)

By pairing human insight with powerful AI, our automated fraud, waste and abuse audits recover \$2M on average for our clients.

Expert virtual sessions

- [Trends in Drug Spend](#)
- [2026 Drug Pipeline Report](#)
- Policy Update Series
 - [January Policy Update](#)
 - [Register for the series](#)



Your monthly dose

How we deliver value for you.

The U.S. GLP-1 market hit \$52.95 billion in 2025 and is forecasted to surpass \$132.79 billion by 2035. [Stay in the know as these drugs continue to evolve.](#)

Other news and updates

- [The adaptive leadership challenge](#) *(published Jan. 2026)*
- **Honoring Women's History Month**
 - [Pivotal momentum in women's health benefits](#) *(published Oct. 2025)*
 - [Women's Health Solutions](#)

[Latest thinking](#) | [Optum Rx](#)



This message was sent by Optum Rx® | 1 Optum Circle, Eden Prairie, MN 55344, USA
[Contact us](#) | [optum.com/optumrx](#) | © 2026 Optum, Inc. All rights reserved.

The email was sent to: | [Privacy Policy](#)
To manage your preferences, visit the [Optum Preference Center](#).
To be removed from all future electronic marketing communications, [unsubscribe here](#).